SERVICES

International Market Access Consulting offers a wide range of services in the areas of Market Access, Pricing and Reimbursement, and Health Economics and Outcomes Research.

MARKET ACCESS

Strategy development

• Guidance on appropriate pricing and reimbursement strategy
• Recommendations for incorporation of health-economic measures into Phase II and III clinical trials
• Assessment of data needs to support target price and reimbursement status

Payer value message testing

• Conduct payer and health-economic expert advisory boards to assess acceptability of data package, value messages
• Identification of evidence gaps, activities needed to maximize the value proposition

Orphan drugs

• Application of specialized expertise in market access for drugs to treat rare diseases. Our team has ensured market entry success for several orphan drugs.

REIMBURSEMENT

Value dossiers

• Development of global value dossiers that persuasively communicate the value proposition of the technology and the key value messages, supported by scientifically robust evidence

Payer presentations

• Creation of value presentation slide decks and other tools for use in key account management and interaction/negotiation with national and regional payers

Formulary submissions

• Development of  country-specific submission dossiers for National Institute for Health and Clinical Excellence (NICE), Scottish Medicines Consortium (SMC), All Wales Medicines Strategy Group (AWMSG), Academy of Managed Care Pharmacy (AMCP), French National Authority for Health (HAS), Pharmaceutical Benefits Advisory Committee (PBAC), Canadian Agency for Drugs and Technologies in Health (CADTC), etc.

HEALTH ECONOMICS AND OUTCOMES RESEARCH

Strategy development

• Assessment of health outcomes measures and recommendations for their inclusion in clinical development program
• Consultation on appropriate patient-reported outcome (PRO) instruments
• Development of strategy to address outcome data gaps

Literature reviews

• Conduct of literature reviews on disease burden, epidemiology, cost and treatment patterns
• Identification of data gaps and opportunities for value differentiation

Health economic modeling

• Construct de novo economic models (Cost-Effectiveness and Budget Impact Models)
• Adaptation of existing budget impact models to local markets to address HTA agency requirements

Observational/administrative database analysis

• Development of study protocols for database analyses or observational studies for collection of real-life data pre- and post-launch

PRICING

Competitor assessment

• Identification of reimbursement status of competitor products by market and patient population
• Analysis of price data for maketplace competitors

 Negotiation strategy

• Provision of continuous support for payer negotiations
• Participation in face-to-face meetings with reimbursement authorities
• Development of risk-sharing agreements, product listing agreements (PLA), and utilization management agreements (UMA) and other programs to address payer needs